Effect of PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitor on acute events in patients with acute myocardial infarction: multicenter randomized controlled trial
Not Applicable
- Conditions
- Acute myocardial infarction
- Registration Number
- JPRN-UMIN000028729
- Lead Sponsor
- Kagawa Prefectural Central Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
Not provided
Exclusion Criteria
cardiogenic shock, dialysis cases, cardiopulmonary arrest, severe liver disease, active malignancy, Unable to ingest statins, patients using PCSK9 inhibitors, patients with side effects on PCSK9 inhibitors in the past , Participating in another trial, a patient who is pregnant or has a possibility of pregnancy, a patient judged inappropriate by another doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Inflammatory markers such as high sensitivity CRP,TNF alpha,PTX3 etc and sdLDL-c, Lp(a), ApoB etc.
- Secondary Outcome Measures
Name Time Method Arrhythmic event or cardiovascular event within 1 month.